{
}
Novo Nordisk's shares have dropped over 20% this year, primarily due to disappointing results for its weight loss drug CagriSema and concerns about Wegovy's market performance against Eli Lilly's Zepbound. Despite this, UBS maintains a "buy" rating with a target price of 750 DKK, suggesting a potential 56% upside. Wall Street remains divided, with half of analysts recommending a buy and the other half advising to hold, but no sell ratings are present.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns, influenced by current trends in weight loss drugs, particularly GLP-1. Analyst Jo Walton noted growth for Eli Lilly's Zepbound, while other competitors are seeing declines.
Goldman Sachs has downgraded Super Micro Computer (SMCI) to "sell," citing risks in the AI server market, increased competition, and low profit margins, with a new price target of $32. Meanwhile, AI startup Fyxer raised $10 million, and major tech firms like Tesla and AMD saw significant stock gains. Apple faces a 21% drop in iPhone shipments in China, while Microsoft and Salesforce are noted for their resilience amid potential software spending slowdowns.
UBS analyst Trung Huynh has reaffirmed a Buy rating on Eli Lilly (NYSE: LLY) with a price target of $1,100. The positive outlook reflects confidence in the company's performance and potential growth in the market.
Hims & Hers Health stock fell 7.4% after Bank of America raised its price target by only $1 to $22, which is $10 below its current value. The bank reiterated its "underperform" rating, citing concerns over slowing growth due to the FDA's actions affecting GLP-1 product sales. With the stock trading at 65 times trailing earnings, analysts question its investment worthiness at this price.
U.S. stocks mostly rose following positive inflation data, with the S&P 500 up 0.1% and the Dow Jones gaining 221 points. However, Eli Lilly's 6.6% drop and declines in several Big Tech stocks limited gains. Treasury yields stabilized after the inflation report, while H&E Equipment Services surged over 100% due to a buyout announcement.
U.S. stocks rose slightly following positive wholesale inflation data, with the S&P 500 up 0.1% and the Dow Jones gaining 134 points. However, declines in major companies like Eli Lilly and Nvidia limited gains. H&E Equipment Services surged over 100% after a buyout announcement, while Signet Jewelers fell 21.5% due to disappointing holiday sales.
The J.P. Morgan Healthcare Conference's second day featured presentations from GSK, Novartis, Sanofi, and Eli Lilly, following a day of significant deal announcements and financial overviews from major biopharma companies. As the first day concluded, attendees faced protests accusing the industry of prioritizing profits over lives, amid heightened police presence due to recent events, including the killing of UnitedHealthcare CEO Brian Thompson. Despite the protests, conference participants remained largely unaffected.
Applied Digital shares surged after Macquarie Asset Management announced a potential $5 billion investment in its HPC data centers. In contrast, Eli Lilly's stock fell nearly 7% following a lowered revenue forecast, while Boeing faced declines due to reduced plane deliveries. KB Home's shares rose on strong earnings, and H&E Equipment's stock doubled after a $4.8 billion acquisition by United Rentals. Signet Jewelers' shares plummeted 22% after cutting its sales outlook due to weak holiday demand, and BP's stock dipped on forecasts of lower production and impairments.
Alzheimer’s drug development is gaining investor attention, with Biogen's Leqembi and Eli Lilly's Kisunla leading the market despite their limitations in reversing the disease. Novo Nordisk is exploring semaglutide's potential benefits for early Alzheimer’s patients, while Roche and UCB are assessing new treatments amid mixed trial results. The landscape is dynamic, with significant opportunities for firms that can deliver effective therapies.
Eli Lilly and Co
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs predicts over 50 percent recovery for novo nordisk shares
19:30 28.03.2025
ubs maintains buy rating for novo nordisk with target price of 750 crowns
16:06 28.03.2025
goldman sachs downgrades super micro computer amid ai market challenges
United States Dollar
XIAOMI-W
Amazon.com, Inc.
Salesforce, Inc.
Tesla, Inc.
Berkshire Hathaway Inc.
Apple Inc.
Meta Platforms, Inc.
Tesmec S.p.A.
Microsoft Corp
Google Inc.
NVIDIA Corporation
AMD/BRX
Eli Lilly and Co
Super Micro Computer, Inc.
Micron Technology, Inc.
USA
Marc Benioff
Marcelo Claure
Michael Ng
Show more
14:51 25.03.2025
UBS maintains buy rating and price target for Eli Lilly
14:03 24.03.2025
hims and hers stock declines after bank of america raises price target
Euro
United States Dollar
Hims & Hers Health, Inc.
Novo Nordisk A/S
Bank of America Corporation
Eli Lilly and Co
USA
Eli Lilly
Show more
16:40 18.03.2025
stocks rise on inflation data despite losses from eli lilly and big tech
United States Dollar
Eli Lilly and Co
NVIDIA Corporation
JPMorgan Chase & Co.
Wells Fargo & Company
United Rentals, Inc.
H&E Equipment Services, Inc.
KB Home
Signet Jewelers Ltd
JPN
CHN
USA
David A. Ricks
Joan Hilson
Show more
22:48 14.01.2025
stocks rise on wall street after positive inflation report
United States Dollar
Eli Lilly and Co
NVIDIA Corporation
JPMorgan Chase & Co.
Wells Fargo & Company
United Rentals, Inc.
H&E Equipment Services, Inc.
KB Home
Signet Jewelers Ltd
JPN
CHN
USA
David A. Ricks
Joan Hilson
Jeffrey T. Mezger
Show more
17:03 14.01.2025
protests mark conclusion of j p morgan healthcare conference day two
16:12 14.01.2025
market update applied digital soars eli lilly and signet jewelers stumble
Boeing Co
BP p.l.c.
H&E Equipment Services, Inc.
Eli Lilly and Co
KB Home
United Rentals, Inc.
Signet Jewelers Ltd
AUS
GBR
USA
Andrew Kessel
Aaron McDade
Jeffrey T. Mezger
Nisha Gopalan
Joan Hilson
Show more
14:57 14.01.2025
alzheimer's drug developments signal potential investment opportunities in 2025
Euro
United States Dollar
Novo Nordisk A/S
Eisai Co., Ltd.
Eli Lilly and Co
BioArctic AB
Hoffmann-La Roche AG
UCB SA
AXA Investment Managers SA
BIOGEN
BEL
JPN
USA
SWE
Gregoire Biollaz
Colin White
Sachin Jain
Jean Rivera Irizarry
Chris Eccleshall
Emily Field
Stacy Kubicek
Show more
18:36 10.01.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
Central Bank Actions
GDP Growth & Recession Forecasts
CEO Changes
Global Trade Developments
Industry Mergers & Acquisitions
Financial Scams and Security
Market Analysis and Predictions
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Domestic Politics
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Barclays PLC
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Credit Suisse Strategic Income I
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
Swiss Re AG
Beazley plc
UBS AG
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Canadian Dollar
Australian Dollar
United Arab Emirates Dirham
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Hong Kong Dollar
Mexican Peso
Indonesian Rupiah
Malaysian Ringgit
Vietnamese Đồng
People: